Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.
OBJECTIVE
Insulin-like growth factor-1 receptor (IGF-1R) displays a key role in tumor transformation and metastasis. It also makes tumor cells more resistant to chemotherapy. The aim of this study was to investigate the correlation between IGF-1R and multidrug resistance-associated protein-1 (MRP-1), and the clinical significance of their expression in gastric carcinoma (GC).


METHODS
IGF-1R and MRP-1 expressed in 113 specimens were detected by immunohistochemistry. The correlation between IGF-1R and MRP-1 expression was determined. In addition, the association of their expression with clinicopathological features and survival data of GC was also analyzed.


RESULTS
IGF-1R (75.2%) and MRP-1 (69.0%) were frequently expressed in GC. IGF-1R was associated with tumor size, quantity of stroma, depth of wall invasion, lymph node metastasis, TNM stages and differentiation status of GC (p < 0.05). MRP-1 was associated with tumor size, quantity of stroma, lymph node metastasis, distant metastasis and TNM stages (p < 0.05). IGF-1R over-expression positively correlated with MRP-1 over-expression (rp = 0.39, p < 0.01). IGF-1R and MPR-1 over-expression were correlated with poor prognosis of GC (p < 0.01). 102 patients receiving adjuvant FOLFOX-4 chemotherapy who co-expressed IGF-1R/MRP-1 had poor prognosis (p < 0.05).


CONCLUSIONS
The levels of co-expression of IGF-1R/MRP-1 in GC may predict the therapeutic effect of chemotherapy and prognosis of GC.
Ge
Jie
J
Department of General Surgery, Xiangya Hospital, Central South University, Changsha, PR China.
Chen
Zhikang
Z
Wu
Shaobin
S
Chen
Jinxiang
J
Li
Xiaoli
X
Li
Jun
J
Yin
Jiye
J
Chen
Zihua
Z
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D002955:Leucovorin / Q000008:administration & dosage; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism*; D011379:Prognosis; D017526:Receptor, IGF Type 1 / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate
D002166:Camptothecin; D005472:Fluorouracil; D002955:Leucovorin; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D017526:Receptor, IGF Type 1; C421109:multidrug resistance-associated protein 1